Leelamine: Difference between revisions
Appearance
Content deleted Content added
m Task 18 (cosmetic): eval 2 templates: hyphenate params (1×); |
move systematic name |
||
(4 intermediate revisions by 4 users not shown) | |||
Line 2: | Line 2: | ||
| ImageFile = Dehydroabietylamine.svg |
| ImageFile = Dehydroabietylamine.svg |
||
| ImageSize = 200px |
| ImageSize = 200px |
||
⚫ | |||
| |
| SystematicName = 1-[(1''R'',4a''S'',10a''R'')-1,4a-Dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methanamine |
||
⚫ | |||
| OtherNames = (+)-Dehydroabietylamine; Amine D |
| OtherNames = (+)-Dehydroabietylamine; Amine D |
||
|Section1={{Chembox Identifiers |
|Section1 = {{Chembox Identifiers |
||
| CASNo = 1446-61-3 |
| CASNo = 1446-61-3 |
||
| CASNo_Ref = {{cascite|correct|CAS}} |
| CASNo_Ref = {{cascite|correct|CAS}} |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = 33289O147P |
| UNII = 33289O147P |
||
| PubChem = 62034 |
| PubChem = 62034 |
||
| ChemSpiderID = 55878 |
| ChemSpiderID = 55878 |
||
| SMILES = CC(C)c1ccc2c(c1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)CN)C |
| SMILES = CC(C)c1ccc2c(c1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)CN)C |
||
| InChI = 1/C20H31N/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4/h6,8,12,14,18H,5,7,9-11,13,21H2,1-4H3/t18-,19-,20+/m0/s1 |
| InChI = 1/C20H31N/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4/h6,8,12,14,18H,5,7,9-11,13,21H2,1-4H3/t18-,19-,20+/m0/s1 |
||
| InChIKey = JVVXZOOGOGPDRZ-SLFFLAALBG |
| InChIKey = JVVXZOOGOGPDRZ-SLFFLAALBG |
||
| StdInChI = 1S/C20H31N/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4/h6,8,12,14,18H,5,7,9-11,13,21H2,1-4H3/t18-,19-,20+/m0/s1 |
| StdInChI = 1S/C20H31N/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4/h6,8,12,14,18H,5,7,9-11,13,21H2,1-4H3/t18-,19-,20+/m0/s1 |
||
| StdInChIKey = JVVXZOOGOGPDRZ-SLFFLAALSA-N |
| StdInChIKey = JVVXZOOGOGPDRZ-SLFFLAALSA-N |
||
}} |
}} |
||
|Section2={{Chembox Properties |
|Section2 ={{Chembox Properties |
||
| C=20 | H=31 | N=1 |
| C=20 | H=31 | N=1 |
||
| Appearance = |
| Appearance = |
||
| Density = |
| Density = |
||
| MeltingPt = |
| MeltingPt = |
||
| BoilingPt = |
| BoilingPt = |
||
| Solubility = |
| Solubility = |
||
}} |
}} |
||
|Section3={{Chembox Hazards |
|Section3 ={{Chembox Hazards |
||
| MainHazards = |
| MainHazards = |
||
| FlashPt = |
| FlashPt = |
||
| AutoignitionPt = |
| AutoignitionPt = |
||
}} |
}} |
||
Line 42: | Line 42: | ||
==See also== |
==See also== |
||
[[Abietic acid]] |
* [[Abietic acid]] |
||
== |
==References== |
||
<references /> |
<references /> |
||
==External links== |
|||
*[https://simpleleaf.com/ Simple Leaf CBD] |
|||
{{Cannabinoids}} |
{{Cannabinoids}} |
||
{{Cannabinoidergics}} |
{{Cannabinoidergics}} |
||
⚫ | |||
[[Category:Cannabinoids]] |
[[Category:Cannabinoids]] |
||
[[Category:Diterpene alkaloids]] |
[[Category:Diterpene alkaloids]] |
||
⚫ | |||
[[Category:Isopropyl compounds]] |
[[Category:Isopropyl compounds]] |
||
[[Category:Phenanthrenes]] |
|||
{{cannabinoid-stub}} |
{{cannabinoid-stub}} |
Latest revision as of 14:33, 3 May 2023
Names | |
---|---|
IUPAC name
Abieta-8,11,13-trien-18-amine
| |
Systematic IUPAC name
1-[(1R,4aS,10aR)-1,4a-Dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methanamine | |
Other names
(+)-Dehydroabietylamine; Amine D
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.014.454 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H31N | |
Molar mass | 285.475 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Leelamine (dehydroabietylamine) is a diterpene amine that has weak affinity for the cannabinoid receptors CB1 and CB2, as well as being an inhibitor of pyruvate dehydrogenase kinase.[1] Optically active leelamine is also used as a chiral resolving agent for carboxylic acids.[2][3] Leelamine has been shown to be effective against certain cancer cells, independent from its activity on CB receptors or PDK1 - it accumulates inside the acidic lysosomes leading to disruption of intracellular cholesterol transport, autophagy and endocytosis followed by cell death.[4]
See also
[edit]References
[edit]- ^ "Leelamine - Dehydroabietylamine - Cayman Chemical". Retrieved May 20, 2013.
- ^ US patent 3454626
- ^ US patent 4559178
- ^ Kuzu, O. F.; Gowda, R.; Sharma, A.; Robertson, G. P. (2014). "Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport". Molecular Cancer Therapeutics. 13 (7): 1690–703. doi:10.1158/1535-7163.MCT-13-0868. PMC 4373557. PMID 24688051.